Skip to main content
. 2021 Jun 3;11(6):e046641. doi: 10.1136/bmjopen-2020-046641

Table 2.

Treatment of patients with AMI during hospital stay by age groups

Age groups P value Total sample
(n=5530)
65–74 (n=3709) 75–84 (n=1821)
Drug treatment of patients with AMI
 Antiplatelets 3661 (98.7%) 1806 (99.1%) 0.158 5467 (98.8%)
 Ca-antagonists 1343 (36.2%) 748 (41.1%) <0.001 2091 (37.8%)
 ACE inhibitors 3007 (81.1%) 1337 (73.4%) <0.001 4344 (78.5%)
 Beta-blockers 3492 (94.1%) 1683 (92.4%) 0.016 5175 (93.6%)
 Nitrates 2948 (79.5%) 1237 (67.9%) <0.001 4185 (75.7%)
 Angiotensin II antagonists 404 (10.9%) 327 (17.9%) <0.001 731 (13.2%)
 Other antihypertensives 635 (17.1%) 395 (21.7%) <0.001 1030 (18.6%)
 Statins 3284 (88.5%) 1614 (88.6%) 0.956 4898 (88.6%)
 Insulin 1250 (33.7%) 610 (33.5%) 0.904 1860 (33.6%)
Recanalisation therapy of patients with AMI
 At least one recanalisation therapy 2941 (79.3%) 1271 (69.8%) <0.001 4212 (76.2%)
 PCI 2294 (61.8%) 1064 (58.4%) 0.015 3358 (60.7%)
 Bypass 672 (18.1%) 236 (13.0%) <0.001 908 (16.4%)
 Thrombolytic therapy 160 (4.3%) 8 (0.4%) <0.001 168 (3.0%)

AMI, acute myocardial infarction; PCI, percutaneous coronary intervention.